Aggeliki Gkouziouta

Aggeliki Gkouziouta

Auto-generated profile, based on publicly available information

Aggeliki Gkouziouta

Heart Failure, MCS and Transplant Unit, Onassis Cardiac Surgery Center, Athens, Greece

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2018 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
MCMaria G. Crespo-Leiro
Maria G. Crespo-Leiro
MMMarco Metra
Marco Metra
LLLars H. Lund
Lars H. Lund
DMDavor Milicic
Davor Milicic
MCMaria Rosa Costanzo
Maria Rosa Costanzo
FRFrank Ruschitzka
Frank Ruschitzka
This article updates the Heart Failure Association of the European Society of Cardiology (ESC) 2007 classification of advanced heart failure and describes new diagnostic and treatment options for these patients. Recognizing the patient with advanced heart failure is critical to facilitate timely referral to advanced heart failure centres. Unplanned visits for heart failure decompensation, malignant arrhythmias, co-morbidities, and the 2016 ESC guidelines criteria for the diagnosis of heart failure with preserved ejection fraction are included in this updated definition. Standard treatment is, by definition, insufficient in these patients. Inotropic therapy may be used as a bridge strategy, but it is only a palliative measure when used on its own, because of the lack of outcomes data. Major progress has occurred with short-term mechanical circulatory support devices for immediate management of cardiogenic shock and long-term mechanical circulatory support for either a bridge to transplantation or as destination therapy. Heart transplantation remains the treatment of choice for patients without contraindications. Some patients will not be candidates for advanced heart failure therapies. For these patients, who are often elderly with multiple co-morbidities, management of advanced heart failure to reduce symptoms and improve quality of life should be emphasized. Robust evidence from prospective studies is lacking for most therapies for advanced heart failure. There is an urgent need to develop evidence-based treatment algorithms to prolong life when possible and in accordance with patient preferences, increase life quality, and reduce the burden of hospitalization in this vulnerable patient population.

14 March 2014 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
SAStamatis Adamopoulos
Stamatis Adamopoulos
JSJean-Paul Schmid
Jean-Paul Schmid
PDPaul Dendale
Paul Dendale
DPDaniel Poerschke
Daniel Poerschke
DHDominique Hansen
Dominique Hansen
ILIoannis D. Laoutaris
Ioannis D. Laoutaris

3 November 2009 in Circulation
Verified
Journal Article
Open access
PDF file
KSKonstantinos Spargias
Konstantinos Spargias
EAElias Adreanides
Elias Adreanides
EDEftychia Demerouti
Eftychia Demerouti
AGAngeliki Gkouziouta
Angeliki Gkouziouta
AMAthanassios Manginas
Athanassios Manginas
DCDennis V. Cokkinos
Dennis V. Cokkinos
Background— The prevention of contrast-induced nephropathy, which accounts for considerable morbidity and mortality, remains a vexing problem. Contrast-induced renal vasoconstriction is believed to play a pivotal role in the pathogenesis of contrast-induced nephropathy. The aim of this study was to examine the efficacy of the prostacyclin analog iloprost in preventing contrast-induced nephropathy in patients with renal dysfunction undergoing a coronary procedure. Methods and Results— We conducted a randomized, double-blind, placebo-controlled trial of iloprost in 208 patients with a serum creatinine concentration ≥1.4 mg/dL who underwent coronary angiography and/or intervention. Iloprost 1 ng · kg −1 · min −1 or placebo was administered intravenously beginning 30 to 90 minutes before and ending 4 hours after the procedure. Contrast-induced nephropathy was defined by an absolute increase in serum creatinine ≥0.5 mg/dL or a relative increase ≥25% measured 2 to 5 days after the procedure. Contrast-induced nephropathy occurred in 23 of the 105 patients (22%) in the control group and in 8 of the 103 patients (8%) in the iloprost group (odds ratio, 0.29; 95% confidence interval, 0.12 to 0.69; P =0.005). In the control group, the estimated glomerular filtration rate declined from 49.7±15.5 to 46.6±16.6 mL · min −1 · 1.73 m −2 ( P =0.01). In the iloprost group, the estimated glomerular filtration rate increased marginally from 47.5±14.5 to 48.6±16.1 mL · min −1 · 1.73 m −2 ( P =0.26). The mean absolute estimated glomerular filtration rate decline in the control group was greater than its change in the iloprost group (difference, 4.2 mL · min −1 · 1.73 m −2 ; 95% confidence interval, 1.1 to 7.3; P =0.008). Conclusion— Prophylactic administration of iloprost may protect against contrast-induced nephropathy in high-risk patients undergoing a coronary procedure.

12 February 2022 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
TBTheo M M H de By
Theo M M H de By
FSFelix Schoenrath
Felix Schoenrath
KVKevin M Veen
Kevin M Veen
PMPaul Mohacsi
Paul Mohacsi
JSJulia Stein
Julia Stein
BMBart Meyns
Bart Meyns
In the third report of the European Registry for Patients with Mechanical Circulatory Support of the European Association for Cardio-Thoracic Surgery, outcomes of patients receiving mechanical circulatory support are reviewed in relation to implant era. Procedures in adult patients (January 2011–June 2020) were included. Patients from centres with <60% follow-ups completed were excluded. Outcomes were stratified into 3 eras (2011–2013, 2014–2017 and 2018–2020). Adverse event rates (AERs) were calculated and stratified into early phase (3 months). Risk factors for death were explored using univariable Cox regression with a stepwise time-varying hazard ratio (3 months). In total, 4834 procedures in 4486 individual patients (72 hospitals) were included, with a median follow-up of 1.1 (interquartile range: 0.3–2.6) years. The annual number of implants (range: 346–600) did not significantly change (P = 0.41). Both Interagency Registry for Mechanically Assisted Circulatory Support class (classes 4–7: 23, 25 and 33%; P < 0.001) and in-hospital deaths (18.5, 17.2 and 11.2; P < 0.001) decreased significantly between eras. Overall, mortality, transplants and the probability of weaning were 55, 25 and 2% at 5 years after the implant, respectively. Major infections were mainly noted early after the implant occurred (AER<3 months: 1.44 vs AER>3 months: 0.45). Bilirubin and creatinine levels were significant risk factors in the early phase but not in the late phase after the implant. In its 10 years of existence, EUROMACS has become a point of reference enabling benchmarking and outcome monitoring. Patient characteristics and outcomes changed between implant eras. In addition, both occurrence of outcomes and risk factor weights are time dependent.

13 August 2019 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
MCMaja Cikes
Maja Cikes
NJNina Jakus
Nina Jakus
BCBrian Claggett
Brian Claggett
JBJasper J. Brugts
Jasper J. Brugts
PTPhilippe Timmermans
Philippe Timmermans
OROn Behalf Of The Pchf-Vad Registry
On Behalf Of The Pchf-Vad Registry
Aims To compare characteristics of left ventricular assist device (LVAD) recipients receiving a cardiac implantable electronic device (CIED) with a defibrillator component (implantable cardioverter-defibrillator and cardiac resynchronization therapy with defibrillation, CIED-D) vs. those without one, and to assess whether carrying such a device contiguously with an LVAD is associated with outcomes. Methods and results Overall, 448 patients were analysed (mean age 52 ± 13 years, 82% male) in the multicentre European PCHF-VAD registry. To account for all active CIED-Ds during ongoing LVAD treatment, outcome analyses were performed by a time-varying analysis with active CIED-D status post-LVAD as the time-varying covariate. At the time of LVAD implantation, 235 patients (52%) had an active CIED-D. Median time on LVAD support was 1.1 years (interquartile range 0.5–2.0 years). A reduction of 36% in the risk of all-cause mortality was observed in patients with an active CIED-D [hazard ratio (HR) 0.64, 95% confidence interval (CI) 0.46–0.91; P = 0.012), increasing to 41% after adjustment for baseline covariates (HR 0.59, 95% CI 0.40–0.87; P = 0.008) and 39% after propensity score adjustment (HR 0.61, 95% CI 0.39–0.94; P = 0.027). Other than CIED-D, age, LVAD implant as redo surgery, number of ventricular arrhythmia episodes and use of vasopressors pre-LVAD were remaining significant risk factors of all-cause mortality. Incident ventricular arrhythmias post-LVAD portended a 2.4-fold and 2.6-fold increased risk of all-cause and cardiovascular death, respectively; carrying an active CIED-D remained associated with a 47% and 43% reduction in these events, respectively. Conclusions In an analysis accounting for all active CIED-Ds, including those implanted during LVAD support, carrying such a device was associated with significantly better survival during LVAD support.

20 October 2010 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
GKGeorge K Karavolias
George K Karavolias
PGPanagiota Georgiadou
Panagiota Georgiadou
AGAngeliki Gkouziouta
Angeliki Gkouziouta
PKPanagiotis Kariofillis
Panagiotis Kariofillis
GKGeorgia Karabela
Georgia Karabela
VVVassilis Voudris
Vassilis Voudris
Objective: We sought to investigate the short- and long- term effects of bosentan therapy on endothelial, inflammatory and fibrotic markers in patients with pulmonary arterial hypertension (PAH) and the relation to clinical and hemodynamic responses. Methods: We studied 16 patients with moderate-severe idiopathic PAH, in WHO functional class II-IV, despite conventional treatment. Patients received additional treatment with bosentan, 62.5 mg twice daily for 1 month, followed by 125 mg twice daily for 11 months. Study endpoints included 6-min walking distance (6MWD), mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR) and plasma levels of intracellular cell adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), IL-6 and brain natriuretic peptide (BNP). Patients were assessed at baseline, 2 months and 12 months after initiation of bosentan. Results: At 2 months there was an improvement in 6MWD (p < 0.001) and functional class (p < 0.001) and a marked fall in PVR (p <...